Biotech doesn’t typically fail in the lab. It fails later — after early promise and before approval — when the cost of proving a drug works comes up against a funding system built for an earlier stage.
Julie Segal is an Editor at RealClearMarkets and Institutional Investor. She focuses on finance, asset management, and investing, with particular expertise in alternative investments, hedge funds, and real estate markets. Julie's work has been featured in prominent publications, highlighting her insights into the intricacies of financial markets and investment strategies.













